Obesity drug being withdrawn22nd January 2010
The Medicines and Healthcare Products Regulatory Agency has told doctors to stop prescribing sibutramine amid fears it increases the risk of heart attacks and strokes.
The leading obesity drug works by altering chemical messages to the brain which control cravings for food and has been used by 86,000 people in the past year. The MHRA acted after a review by the European Medicines Agency (EMA) recommended suspending its licence in Europe, though the decision still has to be formally ratified by the European Commission.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: Obesity drug being withdrawn
Author: Mark Nicholls
Article Id: 13856
Date Added: 22nd Jan 2010